key: cord-0747875-lowyaro9
authors: Rathod, Shrinivas; Kakamanu, Saranya; Koul, Rashmi
title: In Regard to "Radiation for Glioblastoma in the Era of COVID-19: Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk"
date: 2020-06-02
journal: Adv Radiat Oncol
DOI: 10.1016/j.adro.2020.05.011
sha: ab3f8efbd132f2c2141a332b8478f085c7eec58c
doc_id: 747875
cord_uid: lowyaro9

nan

We read the article "Radiation for Glioblastoma in the Era of COVID-19: Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk" with great interest. 1 We congratulate authors for drafting guidance for selecting glioblastoma who would benefit from hypofractionated radiation (RT) in the era of COVID-19.

The authors suggested elderly glioblastoma (aged ≥65 years) should strongly be considered for hypofractionated RT regimens, 40 Gray (Gy)/ 15 fractions (Fr). 2 For patients with very poor PS (KPS<50 i.e. ECOG 3-4), palliative regimens authors recommended of either 34 Gy /10 fractions, 25 Gy /5 fr or TMZ with the omission of RT and suggested each supported by prospective trial data. [3] [4] [5] We suggest a cautious interpretation of recommendations for a very poor PS (KPS<50) subset.

We want to highlight these referenced landmark studies did not represent patients with very poor PS. The IAEA trial included patients of age 50 years and KPS of 50-70; elderly and frail age 65 years and KPS of 50-70; elderly age 65 years and KPS of 80-100. With a median OS of 7.9 months with 25Gy/5Fr compared to median OS of 6.4 months with hypofractionated RT 40Gy/15Fr there was no survival difference. 3 Similarly, Nordic trial studied patients of age 60 years and above with WHO performance scores 0-2 (even if neurological deficits gave them a performance score of 3). 4 Importantly, 78% of patients in this study had ECOG of 0-1. Although temozolomide alone is an appropriate option in individuals over 60 with ECOG 0-2, its use in the current pandemic requires careful attention. 11

The temozolomide alone had a higher risk of neutropenia (12%), thrombocytopenia (21%) and infection (19%) . 11 In the current scenario, as temozolomide induced immunosuppression could increase the risk of contracting COVID-19. Thus recommendation of its use in patients with poor PS (KPS<50) deserves extreme caution. 4 

Radiation for Glioblastoma in the Era of COVID-19: Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised

On behalf of all authors, I confirm we do not have any conflict of interest to declare.